INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES

• 2024 Cell And Gene Therapy Report: Advancing The Future Of Medicine

  Cell and gene therapies offer hope for cures, but face significant barriers to broader patient access. Find out how industry leaders are working to overcome these challenges.

• Navigating Commercial Logistics: Key Considerations For Emerging CGT Manufacturers

  A successful cell and gene therapy launch requires a logistics strategy that keeps patients at the center, plans for disruptions, and prepares for future growth and global expansion.

• Precigen Secures FDA Approval For PAPZIMEOS And Redefines RRP Treatment

  Precigen has received FDA approval for PAPZIMEOS, the first therapy for recurrent respiratory papillomatosis, marking a major advance in patient care.

• Discover The Path To Oncology Success

  The oncology landscape is brimming with innovative therapies and new treatment approaches. Successful commercialization requires a well-orchestrated strategy to bring these complex products to market.

• Don't Let Distribution Derail Your CGT Launch

  Overcoming distribution challenges is critical for the success of cell and gene therapies. Learn how to build a flexible, robust strategy to optimize patient access.

• The Building Blocks Of A Robust Analytical Assay

  Analytical assays aren't just important for quality control. Regulators expect them. These tips will help if you're just starting to build your analytical package.

• Rethinking Partnerships In Cell & Gene Therapy

  Discover how a unique partnership model helps cell and gene therapy developers accelerate progress, reduce risk, and bring transformative therapies to market faster.

• Navigating The Complexities Of NK Cell Therapy Development

  Deloitte's Amit Agarwal and Ashraf Husain share expert insights on how NK cell therapy developers can overcome manufacturing, supply chain, and commercialization challenges to successfully scale these promising therapies.

• Optimizing Commercial Distribution As You Prepare To Launch Your CGT

  An effective commercial distribution strategy is crucial for new cell and gene therapies, helping manufacturers navigate challenges and ensure patient access.

• Strategies For Optimizing iPSC Cryopreservation, Storage, And Post-Thaw Quality

  Developing iPSC therapies demands meticulous cryopreservation, smart automation, and risk-based post-thaw quality control to bridge lab development with cGMP manufacturing. The sensitivity of iPSCs requires tailored protocols and a deep understanding of cell behavior under scaled conditions, ensuring consistent, viable products.